B. Braun Infusion Pumps Receive FDA Emergency Use Authorization for Use with Nebulizers to Treat COVID-19

B. Braun Medical Inc. (B. Braun; Bethlehem, PA, USA) has secured Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its Perfusor® Space Syringe Infusion Pump, Infusomat® Space Volumetric Infusion Pump, and Outlook® ES Pump systems for use in the "tracheal delivery of continuous nebulized medications into a nebulizer to treat patients of all ages with or suspected of having the Coronavirus Disease 2019 (COVID-19) and to decrease the exposure of healthcare providers (HCP) to such patients during the COVID-19 pandemic." The EUA also authorizes ground medical transport use of the Infusomat® Space Volumetric Infusion Pump System. The Perfusor® Space Syringe Infusion Pump System is already cleared for ground transport.

Studies have shown that using infusion pumps with nebulizers can help provide steady, controlled delivery of nebulized medication to patients with acute respiratory distress syndrome (ARDS). Some of the most critical COVID-19 patients suffer from severe ARDS.

"We applaud this decisive action taken by the FDA to help some of the most seriously ill COVID-19 patients," said Jean-Claude Dubacher, Chairman and Chief Executive Officer of B. Braun Medical Inc. "The rapid review and authorization of this and other COVID-19 countermeasures demonstrate the agency's commitment to ensure that healthcare providers have the medical devices and treatments they need to fight this disease."

Related Links:
B. Braun Medical Inc.